The satisfactory 2.7 years cash runway is overshadowed by in...
The satisfactory 2.7 years cash runway is overshadowed by increased cash burn rate of 19%. The firm's potential to raise funds for growth via new shares may entail dilution of existing ones. Close monitoring of Zentalis Pharmaceuticals' cash burn situation advised.
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment